Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Andreas Trojan   ^{1, 2} , MD ;   Sven Roth   ³ , BSc ;   Ziad Atassi   ² , MD ;   Michael Kiessling   ² , MD, PhD ;   Reinhard Zenhaeusern   ⁴ , MD ;   Yannick Kadvany   ⁵ , MA ;   Johannes Schumacher   ⁶ , PhD ;   Gerd A Kullak-Ublick   ¹ , Prof Dr Med ;   Matti Aapro   ⁷ , MD ;   Alexandru Eniu   ⁸ , MD

¹ Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

² BrustZentrum Zürichsee, Horgen, Switzerland

³ Faculty of Medicine, University of Zurich, Zurich, Switzerland

⁴ Onkologie, Spital Oberwallis, Brig, Switzerland

⁵ Mobile Health AG, Zurich, Switzerland

⁶ Palleos Healthcare, Wiesbaden, Germany

⁷ Cancer Center, Clinique de Genolier, Genolier, Switzerland

⁸ Hôpital Riviera-Chablais, Rennaz, Switzerland